Vivian Oehler, MD
Medical Oncology · Seattle, WANPI 1619198991
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $19,372 of the $20,668 with a category attached, or 93.7%. 5 manufacturers reported payments, led by Novartis at 50.3% of the total.
Across 21 payments — averaging $984.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$10K
- Takeda Pharmaceuticals U.S.A., Inc.$8K
- E.r. Squibb & Sons, L.L.C.$2K
- Pfizer$126
- Morphosys, US Inc.$121
Across 86 payments — averaging $64,159 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$4M
- Pfizer$1.1M
- E.r. Squibb & Sons, L.L.C.$128K
- Bristol Myers Squibb$94K
- Otsuka Pharmaceutical Co., Ltd.$80K
- GSK$42K
- plus $25K from 1 others
What the payments were for
- Consulting fees$19,37294%
- Travel & lodging$3922%
- Food & beverage$9044%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 9 | $10,401 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $8,034 |
| E.r. Squibb & Sons, L.L.C. | 1 | $1,986 |
| Pfizer | 1 | $126 |
| Morphosys, US Inc. | 2 | $121 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$20,668 in reported general payments places this provider in the 75th percentile of 162 medical oncology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Imatinib Mesylate | 17 | $2,773 |
| Hydroxyurea | 20 | $273 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Seattle
- Bart ScottSeattle$1.3M
- Petros GrivasSeattle$628K
- Vijayakrishna GadiSeattle$573K
- Evan YuSeattle$296K
- Siddhartha DevarakondaSeattle$215K
- David MaloneySeattle$150K
- Gary LymanSeattle$130K
- Rafic FarahSeattle$114K
- Laura ChowSeattle$114K
- Shailender BhatiaSeattle$107K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.